Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 5 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Allogene secures $15 million grant for cancer trial By Investing.com
Investing.com· 2 days agoThe funding is earmarked to support the Phase 1 TRAVERSE trial, which is evaluating the safety and...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
KLAS Las Vegas· 3 days agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 3 days agoThe NDA is supported by results from JUPITER...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoOutside the U.S., KEYTRUDA growth was driven by continued uptake in earlier-stage cancers, including high-risk, early stage, triple-negative breast...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 3 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Cancer drug trial provides lessons for future
Medical Xpress· 3 days agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 3 days agoKeytruda sales gained from rapid uptake across earlier-stage indications like triple-negative breast...
Nisa Investment Advisors LLC Boosts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 6 days agoNisa Investment Advisors LLC raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 284.0% in the 4th quarter, according to the company in its most recent ...